Literature DB >> 27586869

Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations.

Giulia Scioscia1,2, Isabel Blanco1,3,4,5, Ebymar Arismendi3,4, Felip Burgos1,3,4,5, Concepción Gistau1, Maria Pia Foschino Barbaro2, Bartolome Celli6, Denis E O'Donnell7, Alvar Agustí1,3,4,5.   

Abstract

BACKGROUND: Some patients with COPD report frequent acute exacerbations (AECOPD) of the disease (FE), whereas others suffer them infrequently (IE). Because the current diagnosis of exacerbation relies on patient's perception of increased symptoms (mostly dyspnoea), we hypothesised that dyspnoea perception might be different in COPD patients with FE (≥2 exacerbations or 1 hospitalisation due to AECOPD in the previous year) or IE (≤1 exacerbation in the previous year), AECOPD being defined by the institution antibiotics and/or steroids treatment, or hospital admission.
OBJECTIVE: To test the hypothesis that dyspnoea perception is increased in FE and/or decreased in IE with COPD.
METHODS: We compared the perception of dyspnoea (Borg scale), mouth occlusion pressure 0.1 s after the onset of inspiration (P0.1) and ventilatory response to hypercapnia (ΔVE/ΔPETCO2) in 34 clinically stable COPD patients with FE (n=14) or IE (n=20), with similar age, gender, body mass index and degree of airflow limitation. As a reference, we studied a group of age-matched healthy volunteers (n=10) with normal spirometry.
RESULTS: At rest, P0.1 was higher in FE than IE and controls (p<0.01). Compared with controls, the ventilatory response to hypercapnia was equally blunted both in FE and IE (p<0.001). Despite similar spirometry, during rebreathing peak Borg score and ΔBorg were higher (p<0.01) in FE and lower (p<0.01) in IE, than in controls.
CONCLUSIONS: Dyspnoea perception during CO2 rebreathing is enhanced in FE and blunted in IE. These differences may contribute to the differential rate of reported exacerbations in FE and IE. TRIAL REGISTRATION NUMBER: NCT02113839. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COPD Exacerbations; Emphysema

Mesh:

Year:  2016        PMID: 27586869     DOI: 10.1136/thoraxjnl-2016-208332

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

Review 1.  Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward.

Authors:  Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2022-02-01       Impact factor: 21.405

2.  Treating breathlessness via the brain: changes in brain activity over a course of pulmonary rehabilitation.

Authors:  Mari Herigstad; Olivia K Faull; Anja Hayen; Eleanor Evans; F Maxine Hardinge; Katja Wiech; Kyle T S Pattinson
Journal:  Eur Respir J       Date:  2017-09-12       Impact factor: 16.671

3.  Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease.

Authors:  Roland W Esser; Maria C Stoeckel; Anne Kirsten; Henrik Watz; Karin Taube; Kirsten Lehmann; Helgo Magnussen; Christian Büchel; Andreas von Leupoldt
Journal:  Front Physiol       Date:  2017-08-23       Impact factor: 4.566

4.  MicroRNA-186 is associated with hypoxia-inducible factor-1α expression in chronic obstructive pulmonary disease.

Authors:  Li Lin; Juan Sun; Duoyi Wu; Daobo Lin; Dingwei Sun; Quanni Li; Jiannan Chen; Huan Niu; Ping He; Yipeng Ding
Journal:  Mol Genet Genomic Med       Date:  2018-12-21       Impact factor: 2.183

5.  Inflammation and infections in unreported chronic obstructive pulmonary disease exacerbations.

Authors:  Maria Adelaide Calderazzo; Maria-Belen Trujillo-Torralbo; Lydia Joanne Finney; Aran Singanayagam; Eteri Bakhsoliani; Vijay Padmanaban; Tatiana Kebadze; Julia Aniscenko; Sarah L Elkin; Sebastian L Johnston; Patrick Mallia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-04-10

6.  Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.

Authors:  Alexander J Mackay; Konstantinos Kostikas; Nicolas Roche; Stefan-Marian Frent; Petter Olsson; Pascal Pfister; Pritam Gupta; Francesco Patalano; Donald Banerji; Jadwiga A Wedzicha
Journal:  Respir Res       Date:  2020-04-22

7.  Dyspnea could be accurately assessed by a caregiver in hospitalized patients with respiratory diseases: Interrater reliability and agreement study.

Authors:  Gregory Reychler; Marc Beaumont; Anne-Claire Latiers; Thierry Pieters; Antoine Fremault
Journal:  Braz J Phys Ther       Date:  2021-05-24       Impact factor: 3.377

8.  Enhance Access to Pulmonary Rehabilitation with a Structured and Personalized Home-Based Program-reabilitAR: Protocol for Real-World Setting.

Authors:  Sarah Bernard; Rui Vilarinho; Inês Pinto; Rosa Cantante; Ricardo Coxo; Rosa Fonseca; Sagrario Mayoralas-Alises; Salvador Diaz-Lobato; João Carvalho; Cátia Esteves; Cátia Caneiras
Journal:  Int J Environ Res Public Health       Date:  2021-06-06       Impact factor: 3.390

9.  The EASI model: A first integrative computational approximation to the natural history of COPD.

Authors:  Alvar Agustí; Albert Compte; Rosa Faner; Judith Garcia-Aymerich; Guillaume Noell; Borja G Cosio; Robert Rodriguez-Roisin; Bartolomé Celli; Josep Maria Anto
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

10.  Understanding changes in dyspnoea perception in obstructive lung disease after mindfulness training.

Authors:  Alice Malpass; Gene Feder; James W Dodd
Journal:  BMJ Open Respir Res       Date:  2018-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.